We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

[NAIROBI] The introduction of a vaccine against childhood pneumonia has cut new cases of the disease in a Kenyan county by 27 per cent, a study says.

Pneumonia accounts for 18 per cent of all deaths of children under five years old worldwide each year, with children in Sub-Saharan Africa and South Asia succumbing to the disease the most, according to the WHO.

The study published in the March issue of the Lancet Global Health adds that Kenya introduced a vaccine called PCV10 against pneumonia in January 2011.

“The study shows that there is considerable improvement in child health associated with the implementation of a PCV10 programme, providing important evidence for policymakers.”

Anthony Scott, London School of Hygiene and Tropical Medicine

“The study shows that there is considerable improvement in child health associated with the implementation of a PCV10 programme, providing important evidence for policymakers in Africa as they confront the challenge of sustaining immunisation programmes independently,” says Anthony Scott, corresponding author of the study and professor of vaccine epidemiology at the UK-based London School of Hygiene and Tropical Medicine, in a statement published last month (15 February).

The KEMRI-Wellcome Trust Research Programme in Kenya conducted the study in Kenya’s Kilifi County in partnership with other institutions.

Shirine Voller, manager of the Epidemiology and Demography Department at the KEMRI Wellcome Trust Research Programme, tells SciDev.Net that when Kenya was planning to introduce the vaccine into its routine immunisation schedule, there was very limited evidence about its use and impact in Sub-Saharan Africa.

Researchers linked surveillance of severe or very severe childhood pneumonia at Kenya’s Kilifi County Hospital from 2002 to 2015 to the Kilifi Health and Demographic Surveillance System, which has a population of 45,000 children younger than five years.

“The study was initiated before [the vaccine] was introduced in Kenya, meaning it was possible to make a before-after comparison of the incidence of pneumonia hospitalisations in Kilifi, and therefore to show what impact the vaccine has had in reducing the burden of pneumonia,” she says.

According to the study, the introduction of the vaccine led to reduction of new childhood pneumonia cases from 1220 per 100,000 to 891 per 100,000.

Voller adds that many countries in Sub-Saharan Africa have implemented similar vaccines against pneumonia in their routine immunisation schedules and this study adds some of the first robust evidence about the impact of such a vaccine on incidence of childhood pneumonia in the region. “The KEMRI-Wellcome Trust Research Programme is currently engaging with the Kenya National Immunisation Technical Advisory Group to share our findings about the [vaccine’s] impact and cost-effectiveness,” adds Voller, who is not a co-author of the study. 

Yap Boum II, the regional representative for Epicentre, the research arm of Médecins sans Frontières, says that the findings of the study are significant. 

“Almost 30 per cent reduction [of new cases of pneumonia in children] is huge considering all the implications in terms of vaccine effectiveness and also all the logistics needed to make the vaccine available,” he tells SciDev.Net.
This piece was produced by SciDev.Net’s Sub-Saharan Africa English desk.


Anthony Scott and others Effect of 10-valent pneumococcal conjugate vaccine on the incidence of radiologically-confirmed pneumonia and clinically-defined pneumonia in Kenyan children: an interrupted time-series analysis (Lancet Global Health, March 2019

Related topics